Evidence map›Paper›PMID 40877168›Full record

ArticleIn vivo (Athens, Greece)

Association Between Anticholinergic Drug Use and Febrile Neutropenia Induced by Anticancer Chemotherapy: Analysis of the Japanese Adverse Drug Event Report Database.

Anna Kato-Ogiso, Tomohiro Mizuno, Koki Kato, Fumihiro Mizokami, Sho Hasegawa, Tsuyoshi Nakai, Yosuke Ando, Masakazu Hatano, Takenao Koseki, Shigeki Yamada

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna Kato-OgisoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Tomohiro MizunoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan; tomohiro.mizuno@fujita-hu.ac.jp.
Koki KatoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Fumihiro MizokamiDepartment of Pharmacy, National Center for Geriatrics and Gerontology, Aichi, Japan.
Sho HasegawaDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Tsuyoshi NakaiDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Yosuke AndoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Masakazu HatanoDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Takenao KosekiDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.
Shigeki YamadaDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWe previously reported that benzodiazepines with anticholinergic effects are a risk factor for infection in patients with diffuse large B-cell lymphoma; however, the effects of other anticholinergic drugs and the trend of severe infections, such as febrile neutropenia (FN), have not been investigated. The Japanese Anticholinergic Risk Scale (JARS) was developed by the Japanese Society of Geriatric Pharmacy to screen for potentially inappropriate medications with anticholinergic effects. This study aimed to elucidate the trend of FN induced by anticancer chemotherapy in patients who received anticholinergic drugs listed in the JARS. PATIENTS AND

methodsWe obtained data from the JADER. Reporting odds ratios (RORs) were used to detect safety signals for FN. Anticholinergic drugs were classified into three categories according to their JARS score. Safety signals for FN were considered positive if the lower limit of the 95% confidence interval (CI) of the ROR was >1.

resultsA total of 162,918 cases were included in the dataset. RORs for FN indicated that cases with an anticholinergic risk score of 1 and 3 showed a safety signal (score 1: ROR=1.748, 95%CI=1.659-1.841; score 3: ROR=1.525, 95%CI=1.371-1.696), while no safety signals were observed for those with a risk score of 2 (ROR=1.015, 95%CI=0.863-1.194). Similar trends were observed in cases 70 years old and over and those under 70 years old.

conclusionThe trend of FN in patients who received an anticholinergic drug listed in the JARS was similar among younger and older patients.

Indexed as

Antineoplastic AgentsChemotherapy-Induced Febrile NeutropeniaCholinergic AntagonistsDrug-Related Side Effects and Adverse ReactionsFebrile NeutropeniaNeoplasmsAdultAdverse Drug Reaction Reporting SystemsAgedAged, 80 and overDatabases, FactualEast Asian PeopleFemaleHumansJapanMaleAntineoplastic AgentsCholinergic Antagonistsadverse drug reactionsfebrile neutropeniaJapanese Adverse Drug Event Report DatabaseJapanese Anticholinergic Risk Scalesafety signal

Identifiers

PMID40877168
PMCPMC12396082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.